People | February 18, 2025
Dr. Prabhavathi. R joins HEJJE
Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
Approval is based on positive data from the Phase 3 ECHELON-3 trial
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
Cancer cases in India estimated to reach 1.57 million in 2025
This collaboration aims to bridge modern scientific research with traditional Ayurvedic wisdom, fostering innovative solutions that support holistic well-being
International Meeting of World Pharmacopoeias serves as a vital platform to foster international collaboration in pharmacopoeial science and regulatory harmonization
Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,
Recommendation based on results of Phase 3 CheckMate -9DW clinical trial demonstrating statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population
Subscribe To Our Newsletter & Stay Updated
